glp-1 drugs approved for weight loss GLP1 Drug Use Has Soared Costing Billions GLP-1 Drug Savings: A Complete

Evaluation and management of residual cardiovascular risk in patients with diabetes

J Clin Invest 129, 37863791 (2019)

The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)

Application Analysis The type 2 diabetes mellitus segment had a tremendous growth rate, with a revenue share of 62.3% owing to the well-established role of GLP-1 receptor agonists in improving glycemic control, promoting weight loss, and offering cardiovascular benefits in patients with type 2 diabetes

GLP-1 promotes the release of insulin to regulate blood sugar (glucose) levels and appetite

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition